Gilteritinib becomes first FLT3 targeted therapy for relapsed AML
By Ajay V. Patil US FDA approved FLT3 mutation targeted inhibitor Gilteritinib for the treatment of FLT3 mutation positive relapsed or refractory acute myeloid leukemia (AML). Astellas pharma announced that …
Read More